Sickle cell disease
(SCD) is a group of common, life-threatening
disorders caused by a point mutation in the β globin gene. Early
diagnosis through newborn and early childhood screening, parental
education, and preventive treatments are known to reduce mortality.
However, the cost and complexity of conventional diagnostic methods
limit the feasibility of early diagnosis for SCD in resource-limited
areas worldwide. Although several point-of-care tests are commercially
available, most are antibody-based tests, which cannot be used in
patients who have recently received a blood transfusion. Here, we
describe the development of a rapid, low-cost nucleic acid test that
uses real-time fluorescence to detect the point mutation encoding
hemoglobin S (HbS) in one round of isothermal recombinase polymerase
amplification (RPA). When tested with a set of clinical samples from
SCD patients and healthy volunteers, our assay demonstrated 100% sensitivity
for both the β
A
globin and β
S
globin
alleles and 94.7 and 97.1% specificities for the β
A
globin allele and β
S
globin allele, respectively
(
n
= 91). Finally, we demonstrate proof-of-concept
sample-to-answer genotyping of genomic DNA from capillary blood using
an alkaline lysis procedure and direct input of diluted lysate into
RPA. The workflow is performed in <30 min at a cost of <$5 USD
on a commercially available benchtop fluorimeter and an open-source
miniature fluorimeter. This study demonstrates the potential utility
of a rapid, sample-to-answer nucleic acid test for SCD that may be
implemented near the point of care and could be adapted to other disease-causing
point mutations in genomic DNA.